A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
NCT01626885
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
MP-214
Sponsor
Tanabe Pharma Corporation